News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    

Clinical - Phase III
Eleven Bio (EBIO) Announces Completion Of Vicinium Manufacturing For Ongoing Clinical Trials In Non-Muscle Invasive Bladder Cancer 9/22/2017
Auris Med (EARS) Completes Patient Recruitment For Phase III TACTT3 Trial Of Keyzilen In Acute And Post-Acute Tinnitus 9/22/2017
3 Biotechs With Make-or-Break Trial Results, FDA Meetings Coming Soon 9/22/2017
Bay Area Versartis (VSAR)'s Stock Collapses as Growth Hormone Drug Flunks Phase III Test 9/22/2017
Eli Lilly (LLY) Heads to Finish Line with Breast Cancer Treatment Abemaciclib 9/21/2017
Alnylam (ALNY) Stock Catapults as Genetic Disease Drug Meets All Phase III Goals 9/21/2017
Akari to Push Lead Drug Into Phase III For PNH In Q1 2018, Stock Surges 9/21/2017
GENFIT (ALGFT): Risk Of Confusion Between PPAR Alpha/Delta Phase III Drug Candidate Elafibranor And PPAR A/D/Gamma Phase II Compound Lanifibranor 9/21/2017
Arbutus Biopharma (ABUS)’ LNP Licensee Alnylam (ALNY) Announces Positive Phase III Results For LNP-Enabled Patisiran Program 9/21/2017
MorphoSys AG Announces That Its Licensee Janssen Biotech (JNJ) Has Initiated Two Phase III Studies With Tremfyatm (Guselkumab) In Psoriatic Arthritis 9/21/2017
Theravance Biopharma (TBPH) Highlights Positive Headline Results From IMPACT Study Of Trelegy Ellipta Announced By GlaxoSmithKline (GSK) And Innoviva Inc. (THRX) 9/21/2017
Shire (SHPG), Shionogi's Adult ADHD Drug Hits Phase III Goals 9/20/2017
Supernus (SUPN) Plummets On Drug Study Change 9/20/2017
Soligenix (SNGX) Announces $1.5 Million NIDCR SBIR Grant Award Supporting The Pivotal Phase III Clinical Trial Of SGX942 For The Treatment Of Oral Mucositis In Head And Neck Cancer 9/20/2017
GlaxoSmithKline (GSK) And Innoviva Inc. (THRX) Report Positive Headline Results From IMPACT Study Showing Single Inhaler Triple Therapy Trelegy Ellipta Reduced COPD Exacerbations 9/20/2017
Gemphire Announces Plans To Advance Gemcabene Into Phase III Clinical Development 9/20/2017
Nabriva (NBRV)'s Stock Explodes as Pneumonia Drug Wows in Two Phase III Trials 9/19/2017
Eisai Company (ESALY.PK) Presents Results Of Phase III Clinical Study Of Lenvima (Lenvatinib) In Unresectable Hepatocellular Carcinoma At 11th ILCA Annual Conference 9/19/2017
FDA Grants Fast Track Designation For Amicus (FOLD)’ Migalastat For Treatment Of Fabry Disease 9/19/2017
Argos (ARGS) To Hold Conference Call To Discuss Update On The Phase III Adapt Trial Presented At The ESMO 2017 Congress 9/19/2017
PHARNEXT Amends The Protocol Of The International Pivotal Phase III Trials Of PXT3003 For Charcot-Marie-Tooth Disease Type 1A 9/19/2017
Genentech (RHHBY) Release: Phase III Data Showed That Venclexta Plus Rituxan Helped People With Previously Treated Chronic Lymphocytic Leukemia Live Longer Without Their Disease Worsening Compared To Bendamustine Plus Rituxan 9/19/2017
Cytokinetics (CYTK) Announces Dosing Of First Patient In Japan In GALACTIC-HF, Phase III Clinical Trial Of Omecamtiv Mecarbil In Patients With Heart Failure 9/19/2017
AgeneBio Receives NIH Grant To Initiate Phase III HOPE4MCI Trial To Treat MCI Due To Alzheimer's Disease 9/19/2017
Novartis AG (NVS) Release: New Analysis Shows Entresto Improved Physical And Social Activity In Patients With HFrEF 9/19/2017
Data On Delcath Systems (DCTH)’s CHEMOSAT System Presented At CIRSE Annual Meeting 9/19/2017
Soligenix (SNGX) Announces $1.5 Million NCI SBIR Grant Award Supporting The Pivotal Phase III Clinical Trial Of SGX301 For The Treatment Of Cutaneous T-Cell Lymphoma 9/18/2017
Janssen R&D Release: New Two-Year TREMFYA (guselkumab) Data Show Patients With Moderate To Severe Plaque Psoriasis Achieved Consistent Rates Of Skin Clearance 9/18/2017
FDA Grants Fast Track Designation To Pluristem Therapeutics (PSTI)'s PLX-PAD For The Treatment Of Critical Limb Ischemia (CLI) 9/18/2017
Camurus Announces That FDA Grants Priority Review Of NDA For Weekly And Monthly CAM2038 Buprenorphine Depots For Treatment Of Opioid Use Disorder 9/18/2017
Regeneron (REGN) And Sanofi (SNY) Announce Positive Study Results For DUPIXENT (Dupilumab) In Patients With Moderate-To-Severe Atopic Dermatitis 9/18/2017
Multidisciplinary Association For Psychedelic Studies (MAPS) Selects Montrium's eTMF Platform As They Begin Phase 3 Studies Of MDMA-Assisted Psychotherapy For PTSD 9/18/2017
Theravance Biopharma (TBPH) Highlights GlaxoSmithKline (GSK) And Innovia's Receipt Of Positive Opinion From CHMP In Europe For Trelegy Ellipta (Closed Triple) 9/18/2017
Cytokinetics (CYTK) Announces Presentation Of Additional Results From COSMIC-HF At The HFSA 21st Annual Scientific Meeting 9/18/2017
Melinta Publication Highlights Baxdela Activity Against Fluoroquinolone-Non-Susceptible MRSA Pathogens 9/18/2017
FDA Grants “Fast Track” Status To Cancer Prevention Pharmaceuticals’ Lead Drug CPP-1X/Sul For Treatment Of Familial Adenomatous Polyposis 9/18/2017
Pluristem Therapeutics (PSTI) Surges After Lead Drug Is Granted Fast Track Status 9/18/2017
Novartis AG (NVS)' Xolair Confirms Re-Treatment Efficacy In Chronic Spontaneous Urticaria Patients After Treatment Interruption 9/18/2017
Saniona Reports Encouraging Start For Tesofensine Phase III Study 9/18/2017
AbbVie (ABBV) Announces Positive Topline Results From Phase III Trial Evaluating VENCLEXTA/VENCLYXTO (Venetoclax) Tablets In Combination With Rituxan (Rituximab) For The Treatment Of Patients With Relapsed/Refractory Chronic Lymphocytic Leukemia 9/18/2017
This Regeneron (REGN) Drug Just Took Another Step Toward Blockbuster Status 9/15/2017
Bavarian Nordic (BAVA.CO) Plummets 49% After Cancer Vaccine Flunks Late-Stage Test 9/15/2017
Mirati Therapeutics  (MRTX) Presents Positive Preliminary Data From On-Going Clinical Trials Of Sitravatinib In Non-Small Cell Lung Cancer 9/15/2017
AstraZeneca PLC (AZN) Release: Bydureon EXSCEL Trial Demonstrates Favorable Cardiovascular (CV) Safety Profile And Fewer CV Events In Patients With Type-2 Diabetes At Wide Range Of CV Risk 9/15/2017
TG Therapeutics (TGTX) Announces The Phase III ULTIMATE Trials Evaluating TG-1101 In Patients With Multiple Sclerosis Are Now Open For Enrollment 9/15/2017
Gemphire To Host Investor Conference Call To Discuss Future Development Plans For Gemcabene 9/15/2017
Nymox (NYMX) Announces New Symposium For Company's BPH Drug At American Urological Association Meeting October 5 9/15/2017
Amgen (AMGN) Release: New FOURIER Analysis Shows Repatha (Evolocumab) Reduces Cardiovascular Events In Patients With Diabetes 9/15/2017
New Intarcia Study Evaluates Optimal Way To Switch From Daily Liraglutide Injections To ITCA 650 In Patients With Type 2 Diabetes 9/15/2017
Amicus (FOLD) Dumps Lead Rare Disease Drug After Phase III Trial Failure 9/14/2017
Astellas (ALPMY), Pfizer (PFE)'s Prostate Cancer Drug Hits Late-Stage Trial Goals 9/14/2017
Sandoz Proposed Biosimilar Adalimumab Matches Reference Biologic In Terms Of Efficacy And Safety In Long-Term Study 9/14/2017
Successful Phase III Trial For ALK-Abello A/S’s Tree Allergy SLIT-Tablet 9/14/2017
SELLAS Life Sci' Galinpepimut-S Induces Specific, Robust And Durable Immune Responses In Patients With High-Risk Multiple Myeloma - Correlated With Clinical Benefit 9/14/2017
Fennec Pharma Announces Preliminary Results Of SIOPEL 6 Study On PEDMARK (Sodium Thiosulfate) To Be Presented At The 49TH Congress Of The International Society Of Pediatric Oncology (SIOP) 2017 Meeting 9/14/2017
Alexion (ALXN) Release: Interim Analysis From Phase III Open-Label Extension Study Shows Sustained Benefits Of Soliris (Eculizumab) Treatment For Patients With Refractory Generalized Myasthenia Gravis 9/14/2017
Dermira (DERM), UCB Group (UCBJF.PK) Release: New CIMZIA (Certolizumab Pegol) Findings Presented At European Academy Of Dermatology And Venereology (EADV) Congress 9/14/2017
SAGE Therapeutics (SAGE) Crashes Hard as Lead Epilepsy Drug Flunks Phase III Test 9/13/2017
Novartis AG (NVS) Posts Stunning 5-Year Sustained Late-Stage Psoriasis Data 9/13/2017
Two Deaths Hit AbbVie (ABBV)'s Late-Stage RA Study 9/13/2017
Does SAGE Therapeutics (SAGE)' Failure Predict Its Future Results? 9/13/2017
Clovis Oncology (CLVS)’s Rucaparib ARIEL3 Study Data Published In The Lancet 9/13/2017
AlloSource Announces Milestone In Production Of Bioengineered Blood Vessels For Humacyte's Vascular Access Phase III Clinical Trial 9/13/2017
Daily Blood Glucose Measures In Phase III Clinical Trials Demonstrated Better Stability With Sanofi (SNY)'s Toujeo Vs. Insulin Glargine 100 Units/mL 9/13/2017
AIT Therapeutics’ Adjuvant Nitric Oxide Treatment Shown To Be Safe And Effective In The Compassionate Use Setting In Cystic Fibrosis Patients With Non-Tuberculous Mycobacteria (NTM) Infection 9/13/2017
Dermira (DERM) Presents New Data Showing Impact Of Primary Axillary Hyperhidrosis On Patients 9/13/2017
Sanofi (SNY) and Zealand Pharma  (ZEAL.CO) Release: Soliqua 100/33 Provided Earlier Blood Sugar Control Than Insulin Glargine 100 Units/Ml 9/13/2017
Shionogi Release: S-033188 Phase III CAPSTONE-1 Study Results For Treatment Of Influenza Presented At The European Scientific Working Group On Influenza Conference 9/13/2017
FDA Accepts For Review Astellas (ALPMY)' Supplemental New Drug Application For Mirabegron For Use In Combination With Solifenacin Succinate 5 Mg For The Treatment Of Overactive Bladder 9/13/2017
Lexicon Pharma (LXRX) Release: The New England Journal of Medicine Publishes Data From Phase III InTandem3 Study Of Sotagliflozin In Patients With Type 1 Diabetes 9/13/2017
Amgen (AMGN) Release: EVENITY (romosozumab) ARCH Study Results Published In The New England Journal of Medicine 9/12/2017
Array BioPharma (ARRY) Announces FDA Acceptance For Review Of Binimetinib And Encorafenib New Drug Applications For Patients With Advanced BRAF-mutant Melanoma 9/12/2017
GlaxoSmithKline (GSK) Eyes Regulatory Filings With Mixed Phase III COPD Data 9/12/2017
Onxeo (ONXEO.PA) Plunges After Liver Cancer Drug Fails Late-Stage Study 9/12/2017
Novo Nordisk A/S (NVO) Release: Fiasp Significantly Improved Overall Blood Sugar Control In Type 1 Diabetes Long-Term 9/12/2017
Advicenne Announces Positive Pivotal Phase III Clinical Data For ADV7103 In Adults And Children Suffering From Distal Renal Tubular Acidosis (dRTA) 9/12/2017
Argos (ARGS) Reports On Interim Analysis Of Phase III ADAPT Trial Presented At ESMO 2017 Congress 9/12/2017
Investors are Antsy After Roche (RHHBY) Suffers Another Late-Stage Trial Flop 9/11/2017
Bristol-Myers Squibb (BMY)'s Drug Combo Wows, Cuts Kidney Cancer Death Risk By 37% 9/11/2017
Genentech (RHHBY)'s Macular Degeneration Candidate Flunks Phase III Study 9/11/2017
AstraZeneca PLC (AZN) Restores Cancer Drug Hopes With Impressive Lung Cancer Data 9/11/2017
A Pill Might Control Pancreatic Cancer, Even If It Doesn't Cure It 9/11/2017
TetraPhase (TTPH) Completes Enrollment Of IGNITE3 Phase III Clinical Trial Of Eravacycline In Complicated Urinary Tract Infections 9/11/2017
Seqirus Release: New Phase III Study Shows Significantly Greater Efficacy In Children 6-24 Months Who Receive Adjuvanted Influenza Vaccine (Aqiv) 9/11/2017
Novartis AG (NVS) Phase III Study Demonstrates Adjuvant Tafinlar + Mekinist Reduced The Risk Of Disease Recurrence By 53% In Patients With Resected BRAF V600 Mutation-Positive Melanoma 9/11/2017
Radius Health (RDUS) Presents Positive Data For TYMLOS (Abaloparatide) Injection From The Activextend Trial At ASBMR 2017 Annual Meeting 9/11/2017
Amgen (AMGN) And Allergan (AGN) Present Phase III Data On Biosimilar Trastuzumab Candidate ABP 980 At The European Society For Medical Oncology 2017 Congress 9/11/2017
Array BioPharma (ARRY) Release: Phase III BEACON CRC Safety Lead-In Results In BRAF-Mutant Colorectal Cancer Presented At European Society For Medical Oncology Congress 9/11/2017
Array BioPharma (ARRY) Release: Phase III COLUMBUS Part 2 Results In BRAF-Mutant Melanoma Presented At European Society For Medical Oncology Congress 9/11/2017
Novartis AG (NVS) Phase III Study Demonstrates Adjuvant Tafinlar + Mekinist Reduced The Risk Of Disease Recurrence By 53% In Patients With Resected BRAF V600 Mutation-Positive Melanoma 9/11/2017
Medivir (MVRBF) Announces Janssen To Discontinue Development Of JNJ-4178 For Hepatitis C 9/11/2017
GlaxoSmithKline (GSK) Release: Positive Results From Pioneering Salford Lung Study In Asthma Published In The Lancet, And Presented At European Respiratory Congress 9/11/2017
Eisai Inc. (ESALF.PK) Release: Lenvatinib Delays Deterioration In Certain Domains Of Quality Of Life In Patients With Unresectable Hepatocellular Carcinoma As Compared To Sorafenib In Phase III REFLECT Study 9/11/2017
AstraZeneca PLC (AZN)'s Tagrisso Shows Potential As A New Standard Of Care In First-Line EGFR-Mutated Lung Cancer At ESMO 2017 Congress 9/11/2017
Pfizer (PFE) Presents Positive Pivotal Data For Pf-05280014, An Investigational Biosimilar To Herceptin® (Trastuzumab), At The European Society For Medical Oncology (ESMO) 2017 Congress 9/11/2017
Merck & Co. (MRK)’s Keytruda (Pembrolizumab) Continues To Show Overall Survival Benefit Over Chemotherapy With Nearly Two Years Follow-Up In Previously Treated Patients With Advanced Urothelial Carcinoma, Post-Platinum Failure 9/11/2017
Advicenne Announces Positive Pivotal Phase III Clinical Data For ADV7103 In Adults And Children Suffering From Distal Renal Tubular Acidosis (dRTA) 9/11/2017
Teva (TEVA) Showcases Data Demonstrating Potential Of Fremanezumab To Address Significant Unmet Need In Patients With Chronic And Episodic Migraine 9/11/2017
Regeneron (REGN) And Sanofi (SNY) Announce Positive Dupilumab Topline Results From Phase III Trial In Uncontrolled Persistent Asthma 9/11/2017
AstraZeneca PLC (AZN) Presents New Results Identifying Severe Asthma Patients Who Would Benefit Most From Benralizuma 9/11/2017
Eli Lilly (LLY) Builds Upon Body Of Clinical Evidence For CYRAMZA (Ramucirumab) With Phase III RANGE Data Demonstrating Superior Progression-Free Survival In Advanced Or Metastatic Urothelial Cancer 9/11/2017
AstraZeneca PLC (AZN)’s Tagrisso (Osimertinib) Shows Potential As A New Standard Of Care In 1st-Line EGFR-Mutated Non-Small Cell Lung Cancer At ESMO 2017 Congress 9/11/2017
IHC 2017: Eli Lilly (LLY)'s Lasmiditan Significantly Reduces Pain In Patients With Migraine 9/11/2017
Patient Death Forces Alnylam (ALNY) to Suspend Dosing in Hemophilia Trial, Stock Plunges 9/8/2017
Lexicon Pharma (LXRX) Reports Positive Pooled Continuous Glucose Monitoring Data From Pivotal Phase III inTandem1 And inTandem2 Studies Of Sotagliflozin 9/8/2017
eMD Release: Cladribine Tablets Demonstrates Sustained Disease Control Over Four Years With Maximum Of Only 20 Days Oral Treatment 9/8/2017
Janssen-Cilag International NV (JNJ) Release: New Data Presented At ESMO 2017 Shows That Abiraterone Acetate Plus Prednisone Provides Benefits In Patient Reported Outcomes In Both Metastatic Hormone-Sensitive And Castration-Resistant Prostate Cancer 9/8/2017
Bristol-Myers Squibb (BMY) Release: Two Pivotal Opdivo (Nivolumab) Trials Show Three-Year Survival Benefit In Patients With Previously Treated Advanced Non-Small Cell Lung Cancer 9/8/2017
Clovis Oncology (CLVS) Presents Comprehensive Dataset From Successful Phase III ARIEL3 Maintenance Treatment Trial Of Rucaparib In Advanced Ovarian Cancer At ESMO 2017 9/8/2017
Foundation Medicine (FMI), Roche (RHHBY) Blood Test Could Help 'Personalize' Cancer Immunotherapy 9/8/2017
United Therapeutics (UTHR) Announces Freedom-EV Study Of Orenitram To Continue As Planned Following Interim Analysis 9/8/2017
Versartis (VSAR)’ Twice-Monthly Somavaratan For Pediatric Growth Hormone Deficiency To Be Featured In Oral And Poster Presentations At IMPE 2017 9/8/2017
Puma Biotech (PBYI) Presents 5-Year Analysis Of Phase III Extenet Trial In Extended Adjuvant HER2-Positive Breast Cancer At ESMO 2017 Congress 9/8/2017
Verastem (VSTM) Soars as Blood Cancer Drug Succeeds in Phase III Study 9/7/2017
Nektar (NKTR) Presents Clinical Data From Phase III SUMMIT-07 Study Of NKTR-181, A First-In-Class Investigational Opioid To Treat Chronic Pain, At 2017 PAINWeek 9/7/2017
MiMedx Notified By FDA That It Can Proceed With Phase III Investigational New Drug Clinical Trial For Achilles Tendonitis 9/7/2017
Anthera Surpasses 50% Milestone For Screening Of Patients In RESULT Phase III Clinical Study Of Sollpura In Cystic Fibrosis 9/7/2017
Intra-Cellular Therapies (ITCI) Announces Positive Topline Data From 6-Week Open-Label Safety Switching Study With Lumateperone In Patients With Schizophrenia 9/7/2017
Humacyte Completes Patient Enrollment For Phase III Clinical Trial Of Human Acellular Vessel 9/7/2017
Alder Biopharma (ALDR)To Present Data From Eptinezumab Development Program At 18th Congress Of The International Headache Society 9/7/2017
Dermira (DERM) Presents New Data On Late-Stage Programs At Leading European Dermatology Congress 9/7/2017
Circassia (CIR.L) Announces Duaklir Successfully Met Primary Endpoints In AMPLIFY Phase III Study In Chronic Obstructive Pulmonary Disease 9/7/2017
Bristol-Myers Squibb (BMY) Release: Checkmate -214 Study Evaluating Opdivo In Combination With Yervoy Stopped Early For Demonstrating Overall Survival Benefit In Patients With Previously Untreated Advanced Or Metastatic Renal Cell Carcinoma 9/7/2017
Insmed (INSM) Rockets as Lung Drug Wows in Late-Stage Study 9/6/2017
Augmenix Announces Positive Five-Year Long-Term Data Highlighting Significant Bowel And Sexual Quality Of Life Benefits For Prostate Cancer Patients Treated With Spaceoar Hydrogel 9/6/2017
Symbiomix Announces Publication Of Pivotal Phase III Data For Investigational Solosec For The Treatment Of Bacterial Vaginosis 9/6/2017
Aerie (AERI) Initiates Mercury 3 Clinical Trial Of Roclatantm (Netarsudil/Latanoprost Ophthalmic Solution) 0.02%/0.005% 9/6/2017
Spark Therapeutics (ONCE) Announces Publication Of Study Confirming Novel Test’s Validity, Reliability And Ability To Detect Change In Functional Vision 9/6/2017
ObsEva (OBSV) Announces The Completion Of Patient Recruitment In The IMPLANT2 Phase III Clinical Trial In Assisted Reproductive Technology Ahead Of Schedule 9/6/2017
PHARNEXT Announces That The DSMB Recommends Continuing The Ongoing Phase III Trial Of PXT3003 For Charcot-Marie-Tooth Disease Type 1A 9/6/2017
Citius Pharma Provides Phase III Update On Mino-Lok Clinical Trial Following FDA Meeting 9/5/2017
Global Blood Therapeutics (GBT) Receives Rare Pediatric Disease Designation From FDA For GBT440 For Treatment Of Sickle Cell Disease (SCD) 9/5/2017
Oramed (ORMP) Announces Successful Meeting With FDA For Oral Insulin 9/5/2017
TG Therapeutics (TGTX) Announces Completion Of Target Enrollment In The UNITY-CLL Phase III Trial 9/5/2017
Pluristem Therapeutics (PSTI) Release: $8.7 Million Awarded To Support Phase III Femoral Neck Fracture Trial By EU Horizon 2020 Program 9/5/2017
Novartis AG (NVS) Landmark Phase III Trial Shows Fingolimod Significantly Reduces Relapses In Children And Adolescents With MS 9/5/2017
NW Bio (NWBO) Release: DCVax Clinical Program Updates Presented By Dr. Marnix Bosch At Boston Scientific Conference 9/5/2017
Themis Release: Chikungunya Vaccine Development Towards Phase III Trials Boosted By Innovate UK 9/5/2017
Investors Wait with Bated Breath for AstraZeneca PLC (AZN)'s Cancer Trial Data Next Week 9/1/2017
Amgen (AMGN) Release: Long-Term Analysis Of Phase III Head-To-Head Study Confirms KYPROLIS (Carfilzomib) Regimen Extends Overall Survival In Patients With Relapsed Multiple Myeloma 8/31/2017
Bristol-Myers Squibb (BMY) Data At ESMO 2017 Demonstrate Company’s Innovative Research Approach To Treating Cancer From All Angles 8/31/2017
Puma Biotech (PBYI) Announces Publication Of Abstracts For ESMO 2017 8/31/2017
Daiichi Sankyo Announces Positive Top-Line Results From Phase III Clinical Trial Evaluating Mirogabalin In Diabetic Peripheral Neuropathic Pain 8/31/2017
ASLAN Announces First Patient Enrolled In A Global Phase II/III Study For Varlitinib In Gastric Cancer 8/31/2017
Amyloid Publishes Long-Term Data Analysis From Pfizer (PFE) Suggesting Tafamidis Delays Progression Of TTR-FAP, A Rare Disease 8/31/2017
Otonomy (OTIC) Suspends Development of Lead Drug After Phase III Flop, Stock Plunges 8/31/2017
Amgen (AMGN) Release: New Virtual Histology Sub-Study Evaluates Impact Of Repatha (Evolocumab) On Coronary Artery Plaque Composition 8/30/2017
Amgen (AMGN) Release: New Analysis Shows Repatha (Evolocumab) Reduces Cardiovascular Events In Patients With History Of Stroke 8/30/2017
Clovis Oncology (CLVS) To Present Comprehensive Dataset From Successful ARIEL3 Clinical Trial Program At 2017 ESMO Congress 8/30/2017
Nektar (NKTR) To Present Clinical Data From Phase III SUMMIT-07 Study Of NKTR-181, A First-In-Class Investigational Opioid To Treat Chronic Pain, At Painweek 8/30/2017
Catalyst Pharma (CPRX) Provides Update On The Status Of Its Firdapse Development Activities 8/30/2017
Array BioPharma (ARRY) To Present BEACON CRC Safety Lead-In And COLUMBUS Part 2 Results At European Society For Medical Oncology Congress (ESMO) 8/30/2017
A First: Novartis AG (NVS) Drug May Prevent Heart Attacks and Cut Lung Cancer Risk Too 8/29/2017
Eli Lilly (LLY) Release: New Phase III Data For Abemaciclib And Ramucirumab Presented At ESMO 2017 Congress 8/29/2017
DAIICHI SANKYO EUROPE GmbH Release: New Sub-Analysis Data Highlights The Benefit Of LIXIANA (Edoxaban) Over Warfarin In NVAF Patients According To More Comprehensive Stroke Risk Scoring 8/29/2017
Bristol-Myers Squibb (BMY) And Pfizer (PFE) Alliance Announce Real-World Observational Analysis Of The Effectiveness And Safety Of Direct Oral Anticoagulants Compared To Warfarin In Elderly Patients With Non-Valvular Atrial Fibrillation 8/29/2017
Bayer (BAY) Announces Enrollment Of First U.S. Patient In Phase III Trials Of Vilaprisan In Uterine Fibroids 8/29/2017
Future Unclear For Merck & Co. (MRK)'s Cholesterol Drug As Trial Data Underwhelms 8/29/2017
UroGen Receives FDA Fast Track Designation For Mitogel For The Treatment Of Upper Tract Urothelial Carcinoma (UTUC) 8/29/2017
Biogen (BIIB) Shows Off More Positive Alzheimer’s Trial Data 8/29/2017
DalCor Achieves 50 Percent Enrollment Milestone For Phase III Cardiovascular Trial 8/28/2017
Bayer (BAY) Release: In Canadian-Led Phase III Clinical Study, Xarelto® When Combined With ASA Significantly Lowered The Combined Risk Of Stroke, Cardiovascular Death, And Heart Attack In Patients With Chronic Coronary Or Peripheral Artery Disease By 24% 8/28/2017
How A Potential Drug And A Possible M&A Could Drive Exelixis (EXEL) Even Higher 8/28/2017
Eisai Inc. (ESALF.PK) Release: Lenvatinib Significantly Improved Overall Survival In Older Patients With Locally Recurrent Or Metastatic, Progressive, Radioactive Iodine-Refractory Differentiated Thyroid Cancer According To Results Of Subanalysis Of Phase III SELECT Trial 8/28/2017
Amgen (AMGN) Release: New Repatha (Evolocumab) Analysis Demonstrates Cardiovascular Outcomes Efficacy And Safety Of Achieving Very Low LDL-C Levels 8/28/2017
Bayer (BAY) Release: COMPASS Study Presented At ESC Congress 2017 – Largest Rivaroxaban Study To Date, Enrolled 27,395 Patients To Investigate CAD And PAD 8/28/2017
Alnylam (ALNY) And The Medicines Company (MDCO) Release: New, One-Year Data From ORION-1 Phase II Study Of Inclisiran Extends Excellent Long-Term Efficacy And Safety Profile, Affirming Dose For Phase III Trials 8/28/2017
Genentech (RHHBY) Gains Priority Review For Another Drug, This Time For Lymphoma 8/28/2017
Novartis AG (NVS) Announces Analysis Published In The Lancet Showing ACZ885 Reduced Lung Cancer Mortality By 77% In The CANTOS Study With Further Studies Planned 8/28/2017
The FDA Calls Kyowa Hakko's Lymphoma Drug a Breakthrough 8/25/2017
Tesaro (TSRO) Announces Nine Data Presentations At The 2017 European Society For Medical Oncology (ESMO) Annual Meeting 8/25/2017
This Drug Could be the Most Crucial in Regeneron (REGN)'s Massive Pipeline 8/24/2017
Amgen (AMGN) Release: Overall Survival Analysis From KYPROLIS (Carfilzomib) Phase III Endeavor Trial Published In The Lancet Oncology 8/24/2017
Genmab A/S (GEN.CO) Announces Positive Topline Results In Phase III ALCYONE Study Of Daratumumab In Front Line Multiple Myeloma 8/24/2017
Genentech (RHHBY)'s Hemophilia Contender Wins Priority Review From The FDA 8/24/2017
What's Next For Bristol-Myers Squibb (BMY) After Another Opdivo Setback? 8/23/2017
Octapharma AG Release: Publication Of Clinical Data Demonstrating Low Immunogenicity And Excellent Efficacy Of Nuwiq In Previously Untreated Patients 8/23/2017
Stock Plunges as Phase III Flop Leads Ultragenyx (RARE) to Stop Development of Muscle Disease Drug 8/23/2017
These 3 Biotechs Could Have the Most Exciting Late-Stage Cancer Candidates 8/22/2017
Astellas (ALPMY) Release:First Patient Dosed In Phase III MORPHO Trial Evaluating Gilteritinib As Maintenance Therapy Following Hematopoietic Stem Cell Transplant In Patients With FLT3 Mutation-Positive Acute Myeloid Leukemia 8/22/2017
Alliance Foundation Trials Opens Global Trial Investigating First-In-Class Palbociclib In HR+, HER2+ Metastatic Breast Cancer 8/22/2017
BioLineRx Announces Regulatory Submission Of Phase III Registrational Study For BL-8040 In Stem Cell Mobilization 8/21/2017
Janssen Pharmaceutical Release: New XARELTO (Rivaroxaban) Data At ESC Congress 2017 Includes Late-Breaking Results From Landmark Phase III COMPASS Study 8/21/2017
Boehringer Ingelheim: Advancing Anticoagulation Care With New Data At ESC Congress 2017 8/21/2017
Argos (ARGS) Announces Interim Analysis Of Phase III ADAPT Trial To Be Presented At ESMO 2017 Congress 8/21/2017
Immatics Initiates Personalized Adoptive Cellular Therapy In Patients With Relapsed And/Or Refractory Solid Cancers Using Its Pioneering Target Warehouse 8/21/2017
Tonix Pharma (TNXP) To Present Additional Phase II Clinical Results And Design Of Ongoing Phase III Trial In Military-Related PTSD At The 2017 Military Health System Research Symposium 8/21/2017
Saniona's Partner, Productos Medix, S.A de S.V, Initiates Phase III Study For Tesofensine In Obesity 8/21/2017
Bristol-Myers Squibb (BMY) And Pfizer (PFE) To Highlight Commitment To Reducing The Risk Of Stroke Caused By Non-Valvular Atrial Fibrillation (NVAF) And Treating Deep Vein Thrombosis/Pulmonary Embolism (DVT/PE) At ESC Congress 2017 8/18/2017
Ritter Pharma Announces Phase III Plans After Its End Of Phase II Meeting With FDA On RP-G28 For Lactose Intolerance 8/18/2017
Mithra Pharmaceuticals Announces First Subject Completes Estelle Phase III Study 8/18/2017
Amgen (AMGN) Release: Repatha (Evolocumab) Phase III Cognitive Function Study Results Published In The New England Journal of Medicine 8/17/2017
New Data Shows Previously Allergic Children Still Able To Tolerate Peanut Four Years After Treatment With A Novel Immunotherapy Licensed By Prota Therapeutics 8/17/2017
Biogen (BIIB) Gained $1 Billion Overnight After Becoming Goldman Sachs' Favorite Biotech 8/17/2017
Novo Nordisk A/S (NVO)’s Diabetes Drug Beats Out Eli Lilly (LLY)’s Trulicity in Phase III Trials 8/17/2017
Bristol-Myers Squibb (BMY)'s Stock Topples as Kidney Cancer Drug Flunks Phase III Study 8/16/2017
Lexicon Pharma (LXRX), Sanofi (SNY) Tout More Positive Phase III Diabetes Drug Data 8/15/2017
Ophthotech (OPHT)'s Wet AMD Drug Fails to Meet Primary Endpoint in Phase III Study 8/15/2017
CEL-SCI (CVM) Rockets As The FDA Removes Hold On Phase III Head & Neck Cancer Trial 8/14/2017
Regeneron (REGN) Jumps Despite Ditching Development Of RSV Med 8/14/2017



//-->